Avalo Therapeutics, Inc. $AVTX Stock Position Raised by Allostery Investments LP

Key Points

• Allostery Investments LP raised its position in Avalo Therapeutics by 46.1%, now owning 107,141 shares after increasing their stake by 33,827 shares during the first quarter, making it their 20th largest position.
• Avalon Therapeutics’ stock showed significant movements, reaching a price of $9.02 with a 52-week high of $16.00 and missing earnings expectations with a reported EPS of ($1.92).
• Seven research analysts have rated Avalo Therapeutics with a "Buy" rating, and the average target price has been set at $30.00.

Allostery Investments LP increased its holdings in shares of Avalo Therapeutics, Inc. (NASDAQ:AVTX - Free Report) by 46.1% during the first quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The institutional investor owned 107,141 shares of the company's stock after buying an additional 33,827 shares during the period. Avalo Therapeutics comprises approximately 1.2% of Allostery Investments LP's investment portfolio, making the stock its 20th largest holding. Allostery Investments LP owned approximately 0.99% of Avalo Therapeutics worth $858,000 as of its most recent SEC filing.

Several other institutional investors also recently bought and sold shares of the company. Tower Research Capital LLC TRC grew its holdings in Avalo Therapeutics by 998.4% during the fourth quarter. Tower Research Capital LLC TRC now owns 4,130 shares of the company's stock worth $31,000 after acquiring an additional 3,754 shares during the period. ADAR1 Capital Management LLC purchased a new position in shares of Avalo Therapeutics during the first quarter valued at $80,000. Marshall Wace LLP acquired a new stake in shares of Avalo Therapeutics in the fourth quarter worth about $114,000. Northern Trust Corp acquired a new position in Avalo Therapeutics in the 4th quarter valued at approximately $168,000. Finally, Affinity Asset Advisors LLC grew its position in Avalo Therapeutics by 19.3% during the 1st quarter. Affinity Asset Advisors LLC now owns 657,154 shares of the company's stock worth $5,264,000 after acquiring an additional 106,389 shares during the last quarter. 87.06% of the stock is owned by institutional investors and hedge funds.

Avalo Therapeutics Stock Down 0.3%

Shares of AVTX traded down $0.04 during mid-day trading on Monday, hitting $11.57. 80,668 shares of the company's stock were exchanged, compared to its average volume of 119,875. The stock's 50-day moving average is $7.53 and its 200-day moving average is $6.23. Avalo Therapeutics, Inc. has a fifty-two week low of $3.39 and a fifty-two week high of $16.00.

Avalo Therapeutics (NASDAQ:AVTX - Get Free Report) last announced its earnings results on Thursday, August 7th. The company reported ($1.92) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($1.43) by ($0.49). Analysts forecast that Avalo Therapeutics, Inc. will post -19.07 earnings per share for the current fiscal year.

Wall Street Analyst Weigh In

Several equities research analysts have issued reports on the stock. Cantor Fitzgerald initiated coverage on shares of Avalo Therapeutics in a research report on Friday, August 15th. They set an "overweight" rating for the company. TD Cowen started coverage on shares of Avalo Therapeutics in a report on Friday. They issued a "buy" rating on the stock. Finally, HC Wainwright raised shares of Avalo Therapeutics from a "hold" rating to a "buy" rating and set a $15.00 target price for the company in a report on Monday, June 2nd. Eight equities research analysts have rated the stock with a Buy rating, According to data from MarketBeat, the stock has an average rating of "Buy" and a consensus target price of $30.00.

Avalo Therapeutics Profile

Avalo Therapeutics, Inc, a clinical stage biotechnology company, focuses on the development of therapies for the treatment of immune dysregulation in the Unites States. The company's drug candidates include AVTX-009, an Anti-IL-1ß monoclonal antibody which is under Phase I targeting inflammatory diseases; and AVTX-008, a fully human B and T lymphocyte attenuator agonist fusion protein for the treatment of immune dysregulation disorders.